Glenmark Pharmaceuticals is steering toward a sharper, innovation-driven future over the next four to five years, with a strategic focus on its novel drug portfolio and an expanded branded business. Managing Director Glenn Saldanha unveiled the company’s roadmap during its Investor Day meet in Mumbai.
Branded Portfolio to Dominate by 2030
Under “Glenmark 3.0,” the company plans to raise the share of its branded products from 60% to 70% by 2030. The focus will remain on three core therapeutic areas—dermatology, respiratory, and oncology—where Glenmark is investing heavily to strengthen its leadership position.
“We envision ourselves as a leading global innovation-driven company beyond 2030,” Saldanha affirmed. “Currently, we are a $1.6 billion organisation, with branded products contributing 60% of revenue,” he noted.
Expanding Markets and Novel Drug Pipeline
Glenmark’s next phase of growth hinges on scaling its high-potential EU and emerging markets, bolstering its US generics business through respiratory and injectable launches, and advancing a robust pipeline of innovative multispecific drugs for cancer treatment.
A key driver of this pipeline is Ichnos Glenmark Innovation (IGI), which recently entered a landmark partnership with US-based AbbVie. Under the agreement, AbbVie will co-develop and commercialise ISB 2001, a novel therapy for multiple myeloma. Glenmark will receive an upfront payment of $700 million (₹6,000 crore), along with potential milestone payments of $1.2 billion.
Building Long-Term Value through Innovation
Saldanha emphasized that Glenmark will leverage its innovation platforms to unlock significant market opportunities. These include territories where ISB 2001 alone could generate $5 billion in revenue.
“Glenmark 3.0 is about moving up the value chain, building a large commercial footprint, and transforming into a global innovation-led company,” he said. “At the same time, we aim to create sustainable long-term value for stakeholders with disciplined fiscal management, strong margins, and solid returns.”
A Decade of Transformational Growth Ahead
As reported by The Economic Times, Saldanha described the next decade as pivotal. He said, “The next 10 years will be about creating something transformational. We will launch branded products, strengthen innovation, and move up the value chain. All this will be done while maintaining financial discipline.”
Source : Chemindigest
